Artivion (NYSE:AORT) Sets New 12-Month High - Should You Buy?

Artivion, Inc. (NYSE:AORT - Get Free Report)'s share price reached a new 52-week high on Thursday . The stock traded as high as $32.68 and last traded at $32.70, with a volume of 56185 shares trading hands. The stock had previously closed at $32.15.

Analysts Set New Price Targets

Several analysts have weighed in on AORT shares. Citizens Jmp upgraded Artivion to a "strong-buy" rating in a research note on Tuesday, May 6th. JMP Securities reissued a "market outperform" rating and issued a $33.00 price objective on shares of Artivion in a report on Tuesday, May 6th. Canaccord Genuity Group started coverage on Artivion in a report on Tuesday, June 17th. They issued a "buy" rating and a $35.00 price objective for the company. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $32.00 price target on shares of Artivion in a report on Tuesday, May 6th. Five research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Buy" and a consensus price target of $32.40.

Artivion Stock Down 3.3%

The business has a fifty day simple moving average of $29.50 and a 200 day simple moving average of $27.69. The firm has a market cap of $1.34 billion, a price-to-earnings ratio of -62.94 and a beta of 1.62. The company has a debt-to-equity ratio of 1.08, a current ratio of 5.53 and a quick ratio of 3.95.

Artivion (NYSE:AORT - Get Free Report) last announced its earnings results on Monday, May 5th. The company reported $0.06 EPS for the quarter, missing analysts' consensus estimates of $0.12 by ($0.06). Artivion had a negative net margin of 5.49% and a positive return on equity of 3.63%. The firm had revenue of $98.98 million for the quarter, compared to analyst estimates of $94.81 million. As a group, equities analysts forecast that Artivion, Inc. will post 0.37 EPS for the current fiscal year.

Insider Activity

In other Artivion news, Director Anthony B. Semedo sold 2,600 shares of Artivion stock in a transaction on Friday, May 23rd. The stock was sold at an average price of $28.47, for a total value of $74,022.00. Following the sale, the director owned 33,059 shares in the company, valued at $941,189.73. The trade was a 7.29% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Jean F. Holloway sold 8,748 shares of Artivion stock in a transaction on Tuesday, May 27th. The shares were sold at an average price of $29.00, for a total value of $253,692.00. Following the completion of the sale, the senior vice president owned 178,510 shares in the company, valued at $5,176,790. This represents a 4.67% decrease in their position. The disclosure for this sale can be found here. Insiders sold 72,954 shares of company stock worth $2,108,525 over the last ninety days. Corporate insiders own 7.60% of the company's stock.

Institutional Investors Weigh In On Artivion

Institutional investors have recently modified their holdings of the company. Legacy Advisors LLC acquired a new stake in shares of Artivion in the first quarter valued at $28,000. MCF Advisors LLC grew its stake in shares of Artivion by 109.3% in the first quarter. MCF Advisors LLC now owns 1,176 shares of the company's stock valued at $29,000 after buying an additional 614 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new position in Artivion during the 4th quarter worth $64,000. KLP Kapitalforvaltning AS acquired a new position in Artivion during the 4th quarter worth $194,000. Finally, Raymond James Financial Inc. acquired a new position in Artivion during the 4th quarter worth $275,000. 86.37% of the stock is owned by institutional investors and hedge funds.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.